In the mouse CAIA model, the DPP-1 inhibitor either improved disease parameters or they tended towards improvement; here again, the highest dosage (30 mg/kg/day) yielded the best improvements in arthritis score, rivaling the effect of an anti-TNFα antibody. This evidence concerns the gene CTSC and arthritic joint disease.